Introduction: An enzyme Adenosine deaminase (ADA) converts adenosine to inosine, is an inflammatory enzyme which raised during inflammation. Here, we studied the level of ADA as in inflammatory marker at initiation of therapy, at 12 months of therapy in HIV patients as compared to healthy controls .

Methodology:  150 patients were included in the study and grouped by 50 Pre-ART patients, 50 follow up patients which were on treatment since 12 months and 50 healthy control. Level of ADA was measured in serum were analyzed using ErbaChem 5X semi-automated analyser

Results: Mean age of patients were 38 (SD=4.54) years with majority of patients were males. Pre-ART HIV patients had raised ADA level over 15 IU/L-17 IU/l that decreases at 12 months of treatment. However, A pro-inflammatory systemic profile is exhibited by all at 12 months of treatment. Serum ADA concentration decreases after 12 months of treatment in the follow up patients as compared to pre-ART HIV patients .

Conclusion: Finally, we concluded that level of ADA may be modulated during ART treatment in HIV patients which may affects the inflammatory status of patients.